Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE versus ZYRTEC.
DESLORATADINE vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
5 mg orally once daily.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderatePrimarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category A/B
Category C
Antihistamine
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."